Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Science Ltd
    Anaesthesia 59 (2004), S. 0 
    ISSN: 1365-2044
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 58 (1980), S. 935-941 
    ISSN: 1432-1440
    Keywords: Pseudo-lupus-syndrome ; Antimitochondrial antibodies ; Drug induced allergy ; Pyrazolone ; Specific lymphocyte stimulation ; Pseudo-LE-Syndrom ; Antimitochondriale Antikörper ; Pyrazolon ; Medikamentöse Allergie ; Spezifische Lymphozytenstimulation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 23 Patienten mit Pseudo-Lupus-Syndrom wurden die antimitochondrialen Antikörper in ihrem Titerverlauf über einen Zeitraum von bis zu 5 Jahren beobachtet. Die während der Akutphase sehr hohen AMA-Titer fielen in den meisten Fällen innerhalb der ersten 6 Monate deutlich ab. Nach Reexposition mit Venopyronum-Dragees (VPD) kam es innerhalb von 3 Tagen zu einem Anstieg der Titer bis auf das 5fache des Ausgangswertes. Das in Venopyronum-Dragees enthaltene Analgetikum Phenopyrazon ist das die Antikörper-Produktion auslösende Agens. Der Beweis dafür wurde durch entsprechende Reexpositionsversuche sowie durch die Stimulation von Patienten-Lymphozyten mit phenopyrazonhaltigen Medikamenten erbracht. Zelluläre Immunreaktionen gegenüber dem Medikament konnten bis zu 6 Monate nach akuter Krankheitsphase nachgewiesen werden, fehlten jedoch in den ersten Wochen nach dem durch das Medikament induzierten Schub. Der Übergang in eine chronische Verlaufsform war bei keinem der 23 Patienten zu beobachten. Ein Rezidiv stand immer im Zusammenhang mit einer Medikamenten-Einnahme. Auch andere pyrazonhaltige Medikamente können ein PLE-Syndrom auslösen.
    Notes: Summary 23 patients with proven pseudolupus-syndrome were observed over a period of five years; titers of specific antimitochondrial antibodies (AMA) were tested in a follow-up study after the last intake of Venopyronum-Dragees (VPD), a drug combination of plant glycosides, horse-chestnut extracts and phenopyrazone. Cellular immune reactions against the eliciting drug, depended on the date of the acute phase and were examined in two patients after reexposure. High titers in the acute phase decreased rapidly in most of the cases within the first six months. After reexposure with VPD, AMA rose within three days up to the five fold compared with the initial titer. Only the analgetic component of VPD, phenopyrazone, was able to induce a significant increase of AMA-titer after reexposure. A specific cellular sensitivity to this substance could be demonstrated by lymphocyte stimulation in the presence of a phenopyrazone containing drug preparation. There was no chronic course of the disease; clinical exazerbation could be observed only after new intake of the drug. The analysis of drug history shows, that other pyrazolone containing drugs may also be able to induce a pseudolupus-syndrome.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1573-2568
    Keywords: cerulein pancreatitis ; dibutyltin dichloride ; cytoprotection ; heat shock protein ; hyperthermia ; transforming growth factor-β1
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We recently reported that hyperthermia induces pancreatic expression of heat shock proteins (HSPs), particularly HSP70 isoforms, and protects against cerulein pancreatitis. We have now studied whether a double hyperthermia amplifies these effects and whether hyperthermia also protects against dibutyltin dichloride (DBTC)-induced pancreatitis. A further aim was to examine whether hyperthermia induces changes in transforming growth factor-β1 (TGF-β1). Following pretreatment without or with a single or double hyperthermia, pancreatitis was induced by application of cerulein or DBTC. Pancreatic HSP and TGF-β1 expression were studied by immunoblotting. Pancreas injury was assessed by light microscopy and serum pancreatic enzyme activity. Hyperthermia as well as DBTC induced HSP72, whereas cerulein did not. A double hyperthermia led to a further increase in HSP72 compared to a single heat stress. In both models, hyperthermia significantly reduced pancreatic injury. Although a double hyperthermia slightly decreased the severity of cerulein pancreatitis compared to a single heat treatment, an improved pancreas protection against DBTC cytotoxicity was not achieved. We also found that hyperthermia induces the expression of TGF-β1. In conclusion, hyperthermia preconditioning exerts protective effects against two pathophysiologically different types of pancreatitis by a mechanism that involves the up-regulation of HSP70 isoforms as well as TGF-β1.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...